NASDAQ:CLDX Celldex Therapeutics (CLDX) Stock Price, News & Analysis $22.46 +0.44 (+2.00%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$22.78 +0.32 (+1.42%) As of 08/22/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Celldex Therapeutics Stock (NASDAQ:CLDX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Celldex Therapeutics alerts:Sign Up Key Stats Today's Range$21.56▼$22.7550-Day Range$20.01▼$25.5052-Week Range$14.40▼$47.00Volume1.80 million shsAverage Volume1.31 million shsMarket Capitalization$1.49 billionP/E RatioN/ADividend YieldN/APrice Target$46.67Consensus RatingModerate Buy Company Overview Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey. Read More Celldex Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks32nd Percentile Overall ScoreCLDX MarketRank™: Celldex Therapeutics scored higher than 32% of companies evaluated by MarketBeat, and ranked 772nd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingCelldex Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCelldex Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Celldex Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Celldex Therapeutics are expected to decrease in the coming year, from ($2.48) to ($3.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Celldex Therapeutics is -7.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Celldex Therapeutics is -7.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCelldex Therapeutics has a P/B Ratio of 2.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Celldex Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted12.25% of the float of Celldex Therapeutics has been sold short.Short Interest Ratio / Days to CoverCelldex Therapeutics has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Celldex Therapeutics has recently decreased by 8.15%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCelldex Therapeutics does not currently pay a dividend.Dividend GrowthCelldex Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.25% of the float of Celldex Therapeutics has been sold short.Short Interest Ratio / Days to CoverCelldex Therapeutics has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Celldex Therapeutics has recently decreased by 8.15%, indicating that investor sentiment is improving significantly. News and Social Media1.7 / 5News Sentiment0.05 News SentimentCelldex Therapeutics has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Celldex Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for CLDX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Celldex Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Celldex Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.40% of the stock of Celldex Therapeutics is held by insiders.Read more about Celldex Therapeutics' insider trading history. Receive CLDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celldex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CLDX Stock News HeadlinesCelldex Therapeutics (NASDAQ:CLDX) Price Target Cut to $42.00 by Analysts at HC WainwrightAugust 22 at 2:47 AM | americanbankingnews.comCitigroup Has Lowered Expectations for Celldex Therapeutics (NASDAQ:CLDX) Stock PriceAugust 22 at 2:47 AM | americanbankingnews.com“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning. | InvestorPlace (Ad)Celldex slides after Barzolvolimab hits target but fails to improve EoE symptoms in phase 2 trialAugust 20, 2025 | msn.comCelldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls ShortAugust 20, 2025 | benzinga.comLifeSci Capital Maintains a Buy on Celldex Therapeutics (CLDX), Keeps the PTAugust 20, 2025 | msn.comCelldex Halts Barzolvolimab Development for EoEAugust 19, 2025 | msn.comCelldex Therapeutics Inc (CLDX) Announces Phase 2 Study Results for Barzolvolimab in ...August 19, 2025 | gurufocus.comSee More Headlines CLDX Stock Analysis - Frequently Asked Questions How have CLDX shares performed this year? Celldex Therapeutics' stock was trading at $25.27 at the beginning of 2025. Since then, CLDX stock has decreased by 11.1% and is now trading at $22.46. How were Celldex Therapeutics' earnings last quarter? Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced its quarterly earnings data on Thursday, August, 7th. The biopharmaceutical company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($0.86) by $0.01. The biopharmaceutical company earned $0.73 million during the quarter, compared to analyst estimates of $1.13 million. Celldex Therapeutics had a negative trailing twelve-month return on equity of 27.61% and a negative net margin of 3,446.88%. When did Celldex Therapeutics' stock split? Shares of Celldex Therapeutics reverse split before market open on Monday, February 11th 2019.The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 8th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Celldex Therapeutics' major shareholders? Celldex Therapeutics' top institutional investors include Commodore Capital LP (5.20%), Bellevue Group AG (4.98%), Vestal Point Capital LP (2.64%) and Geode Capital Management LLC (2.52%). Insiders that own company stock include Anthony S Marucci, Samuel Bates Martin, Richard M Wright, Elizabeth Crowley, Margo Heath-Chiozzi and Diane C Young. View institutional ownership trends. How do I buy shares of Celldex Therapeutics? Shares of CLDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Celldex Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Celldex Therapeutics investors own include Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Netflix (NFLX), Alphabet (GOOG) and Visa (V). Company Calendar Last Earnings8/07/2025Today8/23/2025Next Earnings (Estimated)11/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:CLDX CIK744218 Webwww.celldex.com Phone(908) 454-7120Fax908-454-1911Employees150Year Founded1983Price Target and Rating Average Price Target for Celldex Therapeutics$46.67 High Price Target$67.00 Low Price Target$31.00 Potential Upside/Downside+107.8%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($3.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$157.86 million Net Margins-3,446.88% Pretax Margin-3,446.88% Return on Equity-27.61% Return on Assets-26.20% Debt Debt-to-Equity RatioN/A Current Ratio19.67 Quick Ratio19.67 Sales & Book Value Annual Sales$5.79 million Price / Sales257.60 Cash FlowN/A Price / Cash FlowN/A Book Value$9.87 per share Price / Book2.28Miscellaneous Outstanding Shares66,407,000Free Float63,485,000Market Cap$1.49 billion OptionableOptionable Beta1.22 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:CLDX) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celldex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.